{"symbol":"REGN","fiscalQuarter":"Q3-2020","reportDate":"2020-11-05","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q3-2020","postBrief":{"headline":"Regeneron Pharmaceuticals Misses on EPS \u2014 Stock Up 0.28%","keyNumbers":[{"metric":"EPS","actual":"$8.36","expected":"N/A","surprise":"-12.18%"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted ongoing research and development efforts.","They expressed confidence in the long-term potential of their pipeline."],"summary":"Overall, management conveyed a sense of cautious optimism regarding future projects. They emphasized their commitment to innovation despite the EPS miss."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron Pharmaceuticals reported an EPS that was lower than expected, which typically raises concerns among investors. However, the stock still saw a slight increase of 0.28%, likely driven by positive sentiments around their ongoing research initiatives. Investors may be focusing on the company's long-term growth potential despite the short-term earnings miss.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q3 2020 earnings: EPS missed expectations. Stock up 0.28%. Full breakdown."}}